We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » COMPETITORS CAN PLAY ROLE IN OFF-LABEL ENFORCEMENT ACTIONS
COMPETITORS CAN PLAY ROLE IN OFF-LABEL ENFORCEMENT ACTIONS
February 27, 2004
Unsubstantiated comparative product claims can increase the risk of FDA off-label enforcement actions by increasing the incentive for a drugmaker’s competitors to complain to the agency, according to a pharma enforcement expert.